December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad

Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial Featuring: David O'Malley, MD, The Ohio State University Editor’s Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data